MedTrace Logo

SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

NCT06029179 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-02-11

No results posted yet for this study

Summary

This study aims to compare the effects of Sodium Zirconium Cyclosilicate versus Sodium Polystyrene Sulfonate for treatment of hyperkalemia in patients undergoing regular hemodialysis.

Conditions

  • Hyperkalemia

Interventions

DRUG

sodium zirconium cyclosilicate (SZC)

60 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.

DRUG

sodium polystyrene sulfonate

60 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mohamed Mamdouh Elsayed, MD · lecturer

  • Marwa Ahmed Abdelrahman, MD · consultant

  • Mohamed Aly Abdelhalim, MD · Lecturer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2024-10-15
Completion
2024-12-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06029179 on ClinicalTrials.gov